Ultrasound for Prostate Cancer

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA
Prostate Cancer+1 More
Ultrasound - Procedure
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are excreted from the lungs and exhaled back into the air when breathing. Definity may enhance ultrasound images of the prostate and help doctors identify prostate cancer on ultrasound images.

Eligible Conditions

  • Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Up to 12 months

Up to 12 months
Multiparametric ultrasound (mp-US) data to identify sites of significant malignancy within the prostate

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

Diagnostic (perflutren lipid microspheres, ultrasound)
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Ultrasound · No Placebo Group · Phase 3

Diagnostic (perflutren lipid microspheres, ultrasound)Experimental Group · 2 Interventions: Perflutren Lipid Microspheres, Ultrasound · Intervention Types: Drug, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Perflutren Lipid Microspheres
2017
Completed Phase 1
~30
Ultrasound
2013
Completed Phase 4
~2150

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 12 months
Closest Location: Sidney Kimmel Cancer Center at Thomas Jefferson University · Philadelphia, PA
Photo of Philadelphia 1Photo of Philadelphia 2Photo of Philadelphia 3
2014First Recorded Clinical Trial
7 TrialsResearching Prostate Cancer
45 CompletedClinical Trials

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
393 Previous Clinical Trials
126,423 Total Patients Enrolled
5 Trials studying Prostate Cancer
804 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a male at least 18 years of age.
You are scheduled for radical prostatectomy for treatment of prostate cancer.
You are willing and able to give written informed consent for a contrast enhanced ultrasound study of the prostate prior to prostatectomy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.